NCT04006288View on ClinicalTrials.gov

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 6, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

May 16, 2022

Conditions
Coronary Artery Disease
Interventions
DRUG

Clopidogrel

Patients on aspirin and plavix will be randomized to either continue with aspirin and plavix or to switch to aspirin and rivaroxaban

DRUG

Prasugrel

Patients on aspirin and prasugrel will be randomized to either continue with aspirin and prasugrel or to switch to aspirin and rivaroxaban

DRUG

ticagrelor

Patients on aspirin and ticagrelor will be randomized to either continue with aspirin and ticagrelor or to switch to aspirin and rivaroxaban

DRUG

aspirin

all patients will remain on aspirin

DRUG

rivaroxaban

Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban

Trial Locations (1)

32209

University of Florida, Jacksonville

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

University of Florida

OTHER

NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease | Biotech Hunter | Biotech Hunter